Home  |  Contact

Cellosaurus Kuramochi (CVCL_1345)

Cell line name Kuramochi
Synonyms KURAMOCHI
Accession CVCL_1345
Resource Identification Initiative To cite this cell line use: Kuramochi (RRID:CVCL_1345)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Doubling time: 24-27 hours (PubMed=6268719); 82 hours (PubMed=25984343); ~40 hours (lot 06152016), ~43 hours (lot 06302015), 60 hours (lot 10242008) (JCRB).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Homozygous for TP53 p.Asp281Tyr (c.841G>T) (PubMed=24023729).
Disease High grade ovarian serous adenocarcinoma (NCIt: C105555)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,12
D3S135818
D5S81812
D7S82010,11
D8S117910,11
D13S3179,12
D16S53910
D18S5113
D21S1130,32.2
FGA21,23
Penta D10,13
Penta E15
TH019
TPOX8,12
vWA16,19
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=6268719
Motoyama T.
Biological characterization including sensitivity to mitomycin C of cultured human ovarian cancers.
Nihon Sanka Fujinka Gakkai Zasshi 33:1197-1204(1981)

PubMed=7069245
Motoyama T.
Quantitative analysis on in vitro drug sensitivity of cultured human ovarian cancer cell lines.
Nihon Sanka Fujinka Gakkai Zasshi 34:308-314(1982)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=11330945; DOI=10.1006/gyno.2001.6132
Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M., Sato A., Inazawa J.
A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization.
Gynecol. Oncol. 81:172-177(2001)

PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x
Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Jpn. J. Cancer Res. 93:1114-1122(2002)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23839242; DOI=10.1038/ncomms3126
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126-2126(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27561551; DOI=10.1038/ncomms12645
Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat. Commun. 7:12645-12645(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections JCRB; JCRB0098
Cell line databases/resources CCLE; KURAMOCHI_OVARY
CGH-DB; 9357-4
Cosmic-CLP; 909975
GDSC; 909975
LINCS_LDP; LCL-1701
Ontologies EFO; EFO_0006625
Biological sample resources BioSample; SAMN03471055
Chemistry resources ChEMBL-Cells; CHEMBL3308307
ChEMBL-Targets; CHEMBL2366119
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM186430
GEO; GSM186431
GEO; GSM659381
GEO; GSM888319
GEO; GSM1670012
Other Wikidata; Q54900722
Polymorphism and mutation databases Cosmic; 809116
Cosmic; 909975
Cosmic; 931364